The nucleotide sequence of a complementary DNA encoding Flaveria bidentis carbonic anhydrase

A. Cavallaro,M. Ludwig,J. Burnell

DOI: https://doi.org/10.1016/0014-5793(94)00767-5

1994-08-22

FEBS Letters

Abstract:

What problem does this paper attempt to address?

Accurate and Model-free Pose Estimation of Crash Test Dummies

S. Gehrig,H. Badino,Juergen Gall

DOI: https://doi.org/10.1007/978-1-4020-6693-1_19

Abstract:
The 1992 APON Delphi Study to Establish Research Priorities for Pediatric Oncology Nursing

P. Hinds,A. Quargnenti,M. S. Olson,Julie Gross,P. Puckett,E. Randall,J. Gattuso,Dawn Wiedenhoffer

DOI: https://doi.org/10.1177/104345429401100106

1994-01-01

Journal of Pediatric Oncology Nursing

Abstract:The Association of Pediatric Oncology Nurses (APON) recently sponsored a two-wave Delphi study to identify the most important research priorities for pediatric oncology nursing. Seventy-five research priorities were rated for importance by 227 APON members. The majority of these members were inpatient or ambulatory care nurses who had been in pediatric oncology more than 25 months. The top 10 research priorities were primarily about nursing procedures and psychosocial care needs of patients and families. The top priority was to "measure the quality of life and late effects of treatment in long-term survivors of childhood cancer." Study findings will be used to encourage researchers to conduct research on these priorities and to encourage funding organizations to support research related to these priorities.
Dry powder inhalation, part 2: the present and future

Anne Haaije de Boer,Paul Hagedoorn,Floris Grasmeijer

DOI: https://doi.org/10.1080/17425247.2022.2112570

Abstract:Introduction: The manufacture of modern dry powder inhalers (DPIs), starting with the Spinhaler (Fisons) in 1967, was only possible thanks to a series of technological developments in the 20th century, of which many started first around 1950. Not until then, it became possible to design and develop effective, cheap and mass-produced DPIs. The link between these technological developments and DPI development has never been presented and discussed before in reviews about the past and present of DPI technology. Areas covered: The diversity of currently used DPIs with single dose, multiple-unit dose and multi-dose DPIs is discussed, including the benefits and drawbacks of this diversity for correct use and the efficacy of the therapy. No specific databases or search engines otherwise than PubMed and Google have been used. Expert opinion: Considering the relatively poor efficacy regarding lung deposition of currently used DPIs, the high rates of incorrect inhaler use and inhalation errors and the poor adherence to the therapy with inhalers, much effort must be put in improving these shortcomings for future DPI designs. Delivered fine particle doses must be increased, correct inhaler handling must become more intuitive and simpler to perform, and the use of multiple inhalers must be avoided.
Involuntary commitments to public mental institutions: issues involving the overrepresentation of blacks and assessment of relevant functioning.

K. P. Lindsey,G. L. Paul

DOI: https://doi.org/10.1037/0033-2909.106.2.171

IF: 22.4

1989-09-01

Psychological Bulletin

Abstract:This article contributes to the debate in the mental health and legal systems concerning involuntary commitments to mental hospitals. The focus is on issues involving the overrepresentation of Black people among adults committed to U.S. public mental institutions and issues involving the assessment of relevant behavioral functioning in particular. Empirical findings, legal principles and procedures, and methodological limitations are reviewed to identify problems in current practice and relevant evidence bearing on those problems. Special emphasis is placed on the possible explanations for the overrepresentation of Blacks and on dependable assessments of relevant functioning that are needed to justify the state's coercive power to involuntarily confine people, regardless of race. The article concludes with a summary and recommendations for research and practice.
Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial

Kai-Michael Beeh,Piotr Kuna,Massimo Corradi,Isabelle Viaud,Alessandro Guasconi,George Georges

DOI: https://doi.org/10.2147/COPD.S291030

2021-01-14

International Journal of COPD

Abstract:Kai-Michael Beeh, 1 Piotr Kuna, 2 Massimo Corradi, 3 Isabelle Viaud, 4 Alessandro Guasconi, 4 George Georges 4 1 Insaf Respiratory Research Institute, Wiesbaden, Germany; 2 Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Łódź, Poland; 3 Department of Medicine and Surgery, University of Parma, Parma, Italy; 4 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy Correspondence: Kai-Michael Beeh Insaf Respiratory Research Institute, Wiesbaden, Germany Tel +49 611 9854347 Email k.beeh@insaf-wi.de Background: Three 52-week studies in COPD have assessed the efficacy and safety of single-inhaler extrafine formulation triple therapy combining beclomethasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) delivered via pressurized metered-dose inhaler (pMDI). BDP/FF/G is now being developed for delivery via multi-dose dry-powder inhaler (DPI; NEXThaler). This study aimed to demonstrate non-inferiority of BDP/FF/G DPI vs pMDI for lung function. Methods: Multicenter, randomized, double-blind, double-dummy, active-controlled, three-way cross-over study in patients with COPD and post-bronchodilator forced expiratory volume in 1 second (FEV 1 ) 30– 80% predicted. Patients received BDP/FF/G 100/6/10μg via DPI and pMDI, and BDP/FF 100/6μg via pMDI, all two inhalations twice daily for four weeks, with treatments separated by two-week washout. The two co-primary objectives were to demonstrate non-inferiority between the two BDP/FF/G formulations for FEV 1 area under the curve between 0 and 12 hours post-dose (AUC 0-12h ) normalized by time and trough FEV 1 at 24 hours, both on Day 28. EudraCT 2017– 004405-41. Results: Of 449 patients screened, 366 were randomized, with 342 (93.4%) completing all three treatment periods. The primary objectives were met, with changes from baseline in FEV 1 AUC 0– 12h and trough FEV 1 on Day 28 similar for the two BDP/FF/G formulations, and the confidence intervals for the difference lying entirely within the pre-specified non-inferiority criterion (– 50mL): – 20 (– 35, – 6) mL and 3 (– 15, 20) mL for AUC 0– 12h and trough FEV 1 , respectively. BDP/FF/G pMDI and DPI were statistically superior to BDP/FF for these endpoints (p< 0.001). A similar proportion of patients experienced adverse events with each treatment (15.5%, 18.7% and 15.4% with BDP/FF/G DPI and pMDI, and BDP/FF, respectively); the majority were mild or moderate, with few related to treatment. Conclusion: Extrafine BDP/FF/G DPI and pMDI demonstrated similar efficacy and safety in patients with COPD, supporting the DPI formulation as a valid alternative. Keywords: adrenergic beta-2 receptor agonists, muscarinic antagonists, steroids, respiratory function tests, chronic obstructive pulmonary disease
Evaluating dry powder inhalers: From in vitro studies to mobile health technologies

Arzu Ari,Bshayer Ramadan Alhamad

DOI: https://doi.org/10.1016/j.rmed.2023.107281

Abstract:Dry powder inhalers (DPIs) are essential in treating patients with pulmonary diseases. Since DPIs were introduced in the 1960s, a remarkable improvement has been made in their technology, dose delivery, efficiency, reproducibility, stability, and performance based on safety and efficacy. While there are many DPIs on the market and several more under development, it is vital to evaluate the performance of DPIs for effective aerosol drug delivery to patients with respiratory disorders. Their performance evaluation includes the physicochemical properties of the drug powder formulation, metering system, device design, dose preparation, inhalation technique, and patient-device integration. The purpose of this paper is to review current literature evaluating DPIs through in vitro studies, computational fluid models, and in vivo/clinical studies. We will also explain how mobile health applications are used to monitor and evaluate patients' adherence to prescribed medications.
Correlation between Radiographic and Arthroscopic Findings in Asian Osteoarthritic Knees

H. A. Razak,Hwee Yee Christian Heng,Kelin Cheng,A. Mitra

DOI: https://doi.org/10.1177/230949901402200207

2014-08-01

Journal of Orthopaedic Surgery

Abstract:Purpose. To evaluate the correlation between radiographic and arthroscopic findings for severity of knee osteoarthritis (OA) in 119 Asians. Methods. Medical records of 52 men and 67 women aged 33 to 70 (mean, 51) years who had complaints of chronic mechanical knee pain for >3 months and were arthroscopically diagnosed with articular cartilage degeneration of the knee were reviewed. The severity of knee OA was classified using the Kellgren-Lawrence (K&L) scale and the modified Outerbridge classification. The highest grade in any compartment of the knee was used to represent the severity of OA. The correlation between the radiographic and arthroscopic findings for severity of knee OA was evaluated. Results. 17 of the 119 patients with no radiographic evidence of OA (K&L grade 0) had articular cartilage degeneration arthroscopically (mean grade, 1.14). In general, higher K&L grades correlated with more severe articular cartilage degeneration. The Pearson correlation coefficient was 0.32, indicating that the association between the radiographic and arthroscopic findings for severity of knee OA was weak. Conclusion. The K&L scale correlated poorly with arthroscopic findings of articular cartilage degeneration in an Asian population with knee OA.
Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study

Christer Janson,Thomas Lööf,Gunilla Telg,Georgios Stratelis,Folke Nilsson

DOI: https://doi.org/10.1038/npjpcrm.2016.53

2016-11-17

npj Primary Care Respiratory Medicine

Abstract:Multi-dose dry powder inhalers (DPIs) are commonly used in asthma and chronic obstructive lung disease (COPD) treatment. A disadvantage is their sensitivity to humidity. In real life, DPIs are periodically exposed to humid conditions, which may affect aerosol characteristics and lung deposition. This study compared DPI aerosol performance after exposure to humidity. Budesonide (BUD) inhalers (Turbuhaler; Novolizer; Easyhaler) and budesonide/formoterol (BUD/FORM) inhalers (Turbuhaler; Spiromax; Easyhaler) were stored in 75% relative humidity (RH) at both ambient temperature and at −0 °C. Delivered dose (DD) and fine-particle dose (FPD) were tested in vitro before and after storage. BUD inhalers: Turbuhaler and Novolizer showed only small decreases (<15%) in FPD in 40 °C/75% RH, whereas FPD for Easyhaler decreased by >60% (P=0.01) after 1.5 months of storage. Easyhaler also decreased significantly after 6 months of storage in ambient/75%RH by 25% and 54% for DD and FPD, respectively, whereas only small decreases were seen for Turbuhaler and Novolizer (<15%). BUD/FORM inhalers: Turbuhaler and Spiromax DD were unchanged in 40 °C/75% RH, whereas Easyhaler showed a small decrease. FPD (budesonide) decreased for Turbuhaler, Spiromax and Easyhaler by 18%, 10% and 68% (all significant), respectively, at 40 °C/75% RH. In ambient/75%RH, DD was unchanged for all inhalers, whereas FPD (budesonide) decreased for Spiromax (7%, P=0.02) and Easyhaler (34%, (P<0.01)). There are significant differences in device performance after exposure to humid conditions. A clinically relevant decrease of more than half FPD was seen for one of the inhalers, a decrease that may affect patients’ clinical outcomes. Prescriber and patient knowledge on device attributes are essential to ensure optimal drug delivery to the lungs.

primary health care,respiratory system
LD side-pumped Tm,Ho:LuLf pulse laser

L. Qiao,X. Hou,Shijiang Shu,Weibiao Chen

DOI: https://doi.org/10.1109/CLEOPR.2009.5292580

2009-10-30

Abstract:An acousto-optical (AO) Q-swithed Tm,Ho:LuLiF laser at 2 µm range has been obtained in a ring resonator by three LDAs side-pumped. The laser energy is 30 mJ per pulse with the pulse width of 417ns.
Real‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABA

Hae‐Sim Park,Dukyong Yoon,Hyun Young Lee,Ga‐Young Ban,Simon Wan Yau Ming,Joanna Ling Zhi Jie,Victoria Carter,Antony Hardjojo,Job F.M. Van Boven,David B. Price

DOI: https://doi.org/10.1111/resp.13559

IF: 6.9

2019-04-30

Respirology

Abstract:Mixed inhaler device use for asthma is associated with worse inhaler technique and outcomes. Given that relievers are commonly prescribed as pressurized metred‐dose inhalers (pMDI), changing preventers from dry powder inhalers (DPI) to pMDI may improve asthma outcomes. This study aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long‐acting β2‐agonist combination therapy (ICS/LABA). This was a historical cohort study using Ajou University Hospital (Korea) patient records. Persistence of switch was defined as receiving ≥1 pMDI and no DPI after the switch. Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma‐related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch.Within 85 patients who switched from DPI to pMDI and persisted for a year, higher proportion were free from asthma exacerbation after the switch (mean difference in proportion = 0.129, 95% CI: 0.038–0.220). Switching to pMDI was also associated with better RDAC (75.3% vs 57.7%, P = 0.001) and OAC (57.7% vs 45.9%, P = 0.021). From the entire 117 patients who switched to fixed‐dose combination (FDC)/ICS LABA pMDI, 76.1% (95% CI: 69.0–100.0%) patients persisted in the following 6 months. Switching to and persisting with pMDI was associated with decreased asthma exacerbations and improved asthma control. The majority of patients persisted with the switch to pMDI for ICS/LABA treatment.

respiratory system
Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

Amy H. Y. Chan,Roy A. Pleasants,Rajiv Dhand,Stephen L. Tilley,Stephen A. Schworer,Richard W. Costello,Rajan Merchant

DOI: https://doi.org/10.1007/s41030-021-00167-4

2021-08-11

Pulmonary Therapy

Abstract:Impressive advances in inhalation therapy for patients with asthma and chronic obstructive pulmonary disease (COPD) have occurred in recent years. However, important gaps in care remain, particularly relating to poor adherence to inhaled therapies. Digital inhaler health platforms which incorporate digital inhalers to monitor time and date of dosing are an effective disease and medication management tool, promoting collaborative care between clinicians and patients, and providing more in-depth understanding of actual inhaler use. With advances in technology, nearly all inhalers can be digitalized with add-on or embedded sensors to record and transmit data quantitating inhaler actuations, and some have additional capabilities to evaluate inhaler technique. In addition to providing an objective and readily available measure of adherence, they allow patients to interact with the device directly or through their self-management smartphone application such as via alerts and recording of health status. Clinicians can access these data remotely and during patient encounters, to better inform them about disease status and medication adherence and inhaler technique. The ability for remote patient monitoring is accelerating interest in and the use of these devices in clinical practice and research settings. More than 20 clinical studies of digital inhalers in asthma or COPD collectively show improvement in medication adherence, exacerbation risk, and patient outcomes with digital inhalers. These studies support previous findings about patient inhaler use and behaviors, but with greater granularity, and reveal some new findings about patient medication-taking behaviors. Digital devices that record inspiratory flows with inhaler use can guide proper inhaler technique and may prove to be a clinically useful lung function measure. Adoption of digital inhalers into practice is still early, and additional research is needed to determine patient and clinician acceptability, the appropriate place of these devices in the therapeutic regimen, and their cost effectiveness.62kYYJn2XJiRYapXkkXsHTVideo: Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective (MP4 74535 kb)
Enhancing the anaerobic response.

R. Dolferus,E. J. Klok,Christian Delessert,Sarah Wilson,K. Ismond,A. Good,W. Peacock,E. Dennis

DOI: https://doi.org/10.1093/AOB/MCF048

IF: 4.2

2003-01-02

Annals of Botany

Abstract:Proteome analysis, and more recently DNA chip technology, has led to the identification of a large number of genes that are implicated in the anaerobic response of plants. As a result, an increasingly complex picture of the response in terms of biochemical and regulatory processes is emerging. A challenge is to find out more about the function of these newly identified gene products, and how they contribute to flooding tolerance. Our approach has been to manipulate levels of candidate gene products (using sense and antisense constructs) in the model system Arabidopsis thaliana, combined with biochemical and phenotypic analysis of the resulting transgenic plants.
Comparative study of the inhalation parameters of COPD patients through NEXThaler® and Ellipta® dry powder inhalers

Árpád Farkas,Alpár Horváth,Izolda Réti,Norbert Ilyés,Botond Havadtői,Tamás Kovács,Balázs Sánta,Gábor Tomisa,Péter Czaun,Gabriella Gálffy

DOI: https://doi.org/10.1016/j.rmed.2024.107576

IF: 4.3

2024-04-01

Respiratory Medicine

Abstract:The deposition of dry powder aerosol drugs depends on the inhalation parameters of the patients through the inhaler. These data are not directly measured in clinical practice. Their prediction based on the routinely measured spirometric data could help in choosing the appropriate device and optimizing the therapy. The aim of this study was to perform inhalation experiments to find correlations between inhalation parameters of COPD patients through two DPI devices and their native spirometric data, gender, age and disease severity. Another goal was to establish relationships between peak inspiratory flows through NEXThaler® and Ellipta® inhalers and their statistical determinants. Breathing parameters of 113 COPD patients were measured by normal spirometry and while inhaling through the two DPIs. Statistical analysis of the measured data was performed. The average values of peak inspiratory flow through the devices (PIFdev) were 68.4 L/min and 78.0 L/min for NEXThaler® and Ellipta®, respectively. PIFdev values were significantly higher for males than for females, but differences upon age, BMI and disease severity group were not significant. PIFdev values correlated best with their native spirometric counterparts (PIF) and linear relationships between them were revealed. Current results may be used in the future to predict the success of inhalation of COPD patients through DPI devices, which may help in the inhaler choice. By choosing the appropriate device-drug pair for each patient the lung dose can be increased and the efficiency of the therapy improved. Further results of the clinical study will be the subject of a next publication.

cardiac & cardiovascular systems,respiratory system
Information Theory–Based Surrogate Marker Evaluation from Several Randomized Clinical Trials with Binary Endpoints, Using SAS

A. Tilahun,Assam Pryseley,Ariel Alonso,G. Molenberghs

DOI: https://doi.org/10.1080/10543400701697190

2008-03-07

Journal of Biopharmaceutical Statistics

Abstract:One of the paradigms for surrogate marker evaluation in clinical trials is based on employing data from several clinical trials: the meta-analytic approach. It was originally developed for continuous outcomes by means of the linear mixed model, but other situations are of interest. One such situation is when both outcomes are binary. Although joint models have been proposed for this setting, they are cumbersome in the sense of computationally complex and of producing validation measures that are, unlike in the Gaussian case, not of an R 2 type (Burzykowski et al., 2005). A way to put these problems to rest is by employing information theory, already applied in the continuous case (Alonso and Molenberghs, 2007). In this paper, the information-theoretic approach is applied to the case of binary surrogate and true endpoints. Its use is illustrated using a case study in acute migraine and its performance, relative to existing methods, assessed by means of a simulation study. Because the usefulness of a method critically depends, among others, on the availability of software, a SAS implementation accompanies the methodological work.
High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study

Donald A Mahler,Shaban Demirel,Ramon Hollander,Gokul Gopalan,Asif Shaikh,Cathy D Mahle,Jessica Elder,Curtis Morrison

DOI: https://doi.org/10.15326/jcopdf.2022.0291

2022-07-29

Abstract:For optimal drug delivery, dry powder inhalers (DPIs) depend on the patient's peak inspiratory flow (PIF) and the internal resistance of the device to create turbulent energy and disaggregate the powder. A suboptimal PIF may lead to ineffective drug inhalation into the lungs. Our objective was to report the prevalence of suboptimal PIF in patients with COPD hospitalized for any reason using 1 or more DPIs. In this real-world, observational, single‑site, retrospective study, PIF was measured for each DPI using the In-Check™ DIAL set to match the resistance of the DPI used by each patient. PIFs <60 and <30L/min were considered suboptimal for low to medium-high- and high-resistance DPIs, respectively. At initial hospitalization, the prevalence of suboptimal PIF was 44.6% in 829 patients (mean age, 71.7 years; 56.8% female); 21.2% were measured during admission for a COPD exacerbation. Suboptimal PIF percentages were 61.0% (38.1±9.5L/min [mean±standard deviation (SD)]) across low to medium-high-resistance DPIs and 17.2% (20.7±4.2L/min) for high-resistance DPIs. Overall, 190/829 patients had 1 or more 30-day all-cause readmission with 253 corresponding PIF measurements. For readmissions, suboptimal PIFs were observed in 49.5% (94/190) of patients. Suboptimal PIF percentages were 65.4% (38.4±9.2L/min) for low to medium-high-resistance DPIs and 19.8% (22.4±3.3L/min) for high-resistance DPIs. As the overall prevalence of suboptimal PIFs in hospitalized patients with COPD varied according to the specific internal resistance of the DPI, these findings may have clinical implications for inhaler selection.
Early repolarization electrocardiography pattern with unexplained syncope during training in a young black African non-elite athlete: an accidental finding?

A. Bonny,I. Ditah,W. Amara,B. Hamdaoui,R. Frank,J. Le Heuzey

IF: 3.487

Cardiology Journal

Abstract:Until recently it was generally thought that early repolarization is benign. But a recent article in the NEJM (Haissaguerre et al.) suggests that some persons with early repolarization may be at risk of life-threatening ventricular tachyarrhythmia. Unexplained syncope or sudden death occurs mostly during sleep. However, some cases of cardiac arrest during exertion have been reported. We report the case of a 39 year-old black African male with early repolarization pattern on electrocardiogram who regularly experienced dizziness (and one episode of transient loss of consciousness) exclusively while exercising. Detailed examination was normal. Under quinidine therapy, he experienced no further episodes. Increasingly reported cases of cardiac arrest in Africans, and significant prevalence of early repolarization in this population, have to be taken into account since the Haissaguerre et al. report. Further evidence of the lethal consequences of this syndrome are needed, bearing in mind that diagnostic tools for life-threatening arrhythmias are often scarce in sub-Saharan Africa.
The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers

Andrew C Grant,Richard Walker,Melanie Hamilton,Karl Garrill

DOI: https://doi.org/10.1089/jamp.2015.1223

Abstract:Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was developed for the delivery of once-daily therapies for the treatment of asthma and chronic obstructive pulmonary disease. It has moderate resistance to airflow and can hold one or two blister strips, with each blister containing a sealed single dose of medication. Monotherapies can be delivered by the single-strip configuration and, in the two-strip configuration, one dose from each strip can be aerosolized simultaneously to allow combination therapies to be delivered, which enables the formulations for each product to be developed individually, since they are stored separately until the point of administration. There are three principal operating steps to administer a dose: open, inhale, close. This article summarizes the design, functionality, and in vitro dose-delivery characteristics of the ELLIPTA inhaler, and describes the results of human factors validation tests, designed to assess the performance of critical tasks required to use the inhaler. Results from the in vitro studies indicate that the ELLIPTA inhaler performs consistently with respect to in vitro dose delivery characteristics at a range of flow rates that can be achieved by the target population (≥30 L/min) and over its 30-day in-use life. Data from the human factors validation tests demonstrated that almost all participants (≥97%) were able to complete each of the steps required to prepare a dose for inhalation without error. Overall, the ELLIPTA inhaler has a versatile single- or two-strip design that allows it to be used for the delivery of a range of treatment options. It also improves patient ease-of-use when compared with the DISKUS(®) DPI.
Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease

Jill A Ohar,Gary T Ferguson,Donald A Mahler,M Bradley Drummond,Rajiv Dhand,Roy A Pleasants,Antonio Anzueto,David M G Halpin,David B Price,Gail S Drescher,Haley M Hoy,John Haughney,Michael W Hess,Omar S Usmani

DOI: https://doi.org/10.2147/COPD.S319511

2022-01-06

Abstract:Dry powder inhalers (DPIs) are breath actuated, and patients using DPIs need to generate an optimal inspiratory flow during the inhalation maneuver for effective drug delivery to the lungs. However, practical and standardized recommendations for measuring peak inspiratory flow (PIF)-a potential indicator for effective DPI use in chronic obstructive pulmonary disease (COPD)-are lacking. To evaluate recommended PIF assessment approaches, we reviewed the Instructions for Use of the In-Check™ DIAL and the prescribing information for eight DPIs approved for use in the treatment of COPD in the United States. To evaluate applied PIF assessment approaches, we conducted a PubMed search from inception to August 31, 2021, for reports of clinical and real-life studies where PIF was measured using the In-Check™ DIAL or through a DPI in patients with COPD. Evaluation of collective sources, including 47 applicable studies, showed that instructions related to the positioning of the patient with their DPI, instructions for exhalation before the inhalation maneuver, the inhalation maneuver itself, and post-inhalation breath-hold times varied, and in many instances, appeared vague and/or incomplete. We observed considerable variation in how PIF was measured in clinical and real-life studies, underscoring the need for a standardized method of PIF measurement. Standardization of technique will facilitate comparisons among studies. Based on these findings and our clinical and research experience, we propose specific recommendations for PIF measurement to standardize the process and better ensure accurate and reliable PIF values in clinical trials and in daily clinical practice.
Investigation and pharmacy guardianship of dry power inhaler in chronic pulmonary disease

CHEN Suqing,JIN Meiling,YE Xiaofen,SHEN Yao

DOI: https://doi.org/10.3969/j.issn.1007-4406.2008.03.009

2008-01-01

Abstract:AIM To investigate the present situation of chronic pulmonary disease patient' s usage condition and pharmacy guardianship of dry power inhaler(DPI).METHODS By carrying on the investigation of the basic situation,former usage of medicine information and DPI operating procedure and carrying on the data of statistics & analysis for the out-patients who were in Department of Respiratory Medicine of Zhongshan Hospital,Fudan University.RESULTS Among all primary 85 DPI patients,17 cases(20%) completely grasped the inhalation method,44(51.8%) cases had 1-2 operation mistakes,24(28.2%) cases had 3 or above 3 operation mistakes.Among 85 patients,the grasping rates based on the low,middle and high educational level were 45%,70.8%,82.9% respectively(P<0.01).Among 35 patients who had formerly used the DPI,the grasping rate was 100% for the patients who had received the specialized personnel' s medical instruction and on the other hand the grasping rate was 43.8% for the patients who had not received the specialized personnel' s medical instruction(P<0.01).All primary budesonide power for inhalation and salmeterol xinafoate and fluticasone propionate power for inhalation patient' s grasping rate was 66.7% and 86.4% respectively(P>0.05).CONCLUSION The majority of patients are not able to completely grasp DPI application method after reading the booklet themselves.Educational difference would cause remarkable influence on the patient' s grasping DPI application method.Specialized personnel' s instruction is extremely important to grasping DPI application method.The pharmacy guardianship should be crucial for the treatment of asthma and other chronic pulmonary diseases.
Emergency Physicians' Preferences in Bronchodilator Delivery for Asthma Exacerbations: A Cross-Sectional Study

Abdullah K Al-Mutairi,Faisal A AlGhamdi,Dana Althawadi,Mohammad A Alkhofi,Abdullah A Yousef

DOI: https://doi.org/10.1080/02770903.2024.2400605

2024-09-04

Abstract:Asthma is a chronic respiratory disorder characterized by airway inflammation and narrowing often leading to acute exacerbations that necessitate a visit to the emergency department (ED). Whilst life threatening in sever cases, mild to moderate cases can be treated by the administration of bronchodilators delivered by nebulizers or metered dose inhalers (MDI). Numerous studies have attempted to compare between the two modalities and have drawn similar conclusions in that both are comparable in efficacy with minimal differences. What is evident, however, is that physicians remain inclined to favor nebulizers in the majority of acute asthma exacerbations. In this questionnaire-based study, a survey was distributed to physicians who treat asthma exacerbations to examine demographics, knowledge, beliefs and current practice in regard to bronchodilator therapy. Results found the majority (90.8%) of physicians prefer short-acting beta agonists via nebulizer, with 9.2% favoring MDI + spacer. Participants include consultants, residents, and specialists across various emergency disciplines. While 90.1% find MDI + spacer equally effective as nebulizers, advantages cited include cost-effectiveness (49.6%), shorter ED stays (63.4%), quicker administration (67.9%), and ease of use (58.8%). Challenges include availability (66.4%) and ineffectiveness in younger patients (45%). Despite this, 65.6% are willing to switch to MDI for initial asthma management in the ED, while 34.4% are resistant. Concerns about availability and effectiveness in younger patients remain barriers. However, a significant number are willing to adopt MDIs with spacers, indicating potential for broader use with better availability and training.

The nucleotide sequence of a complementary DNA encoding Flaveria bidentis carbonic anhydrase

Accurate and Model-free Pose Estimation of Crash Test Dummies

The 1992 APON Delphi Study to Establish Research Priorities for Pediatric Oncology Nursing

Dry powder inhalation, part 2: the present and future

Involuntary commitments to public mental institutions: issues involving the overrepresentation of blacks and assessment of relevant functioning.

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial

Evaluating dry powder inhalers: From in vitro studies to mobile health technologies

Correlation between Radiographic and Arthroscopic Findings in Asian Osteoarthritic Knees

Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study

LD side-pumped Tm,Ho:LuLf pulse laser

Real‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABA

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

Enhancing the anaerobic response.

Comparative study of the inhalation parameters of COPD patients through NEXThaler® and Ellipta® dry powder inhalers

Information Theory–Based Surrogate Marker Evaluation from Several Randomized Clinical Trials with Binary Endpoints, Using SAS

High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study

Early repolarization electrocardiography pattern with unexplained syncope during training in a young black African non-elite athlete: an accidental finding?

The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers

Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease

Investigation and pharmacy guardianship of dry power inhaler in chronic pulmonary disease

Emergency Physicians' Preferences in Bronchodilator Delivery for Asthma Exacerbations: A Cross-Sectional Study